HI Friends please read
https://multiplesclerosisnewstoday.com/ ... -patients/
A Phase 3 clinical trial has been launched by MedDay Pharmaceuticals to investigate whether treatment with high-dose biotin (MD1003) may ease disability and improve mobility in non-relapsing primary or secondary progressive MS patients. The study is recruiting participants across the U.S., Canada and Europe.
regards
seeva
Phase 3 Study of High-Dose Biotin, MD1003, for PPMS & SPMS
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11798 Views
-
Last post by NHE
-
- 0 Replies
- 2293 Views
-
Last post by NHE
-
- 0 Replies
- 1868 Views
-
Last post by NHE
-
- 0 Replies
- 1948 Views
-
Last post by frodo
-
- 1 Replies
- 1485 Views
-
Last post by ElliotB
-
- 0 Replies
- 4133 Views
-
Last post by NHE
-
- 0 Replies
- 1694 Views
-
Last post by NHE
-
- 1 Replies
- 1285 Views
-
Last post by vesta
-
- 0 Replies
- 1405 Views
-
Last post by NHE